Gold prices edge higher with focus on Ukraine-Russia, Jackson Hole
Amneal Pharmaceuticals (NASDAQ:AMRX) Executive Vice President Nikita Shah sold 71,694 shares of the company’s Class A Common Stock on August 14, 2025, according to a Form 4 filing with the Securities and Exchange Commission. The shares were sold at a weighted average price of $9.29, for a total value of $666,037. The transaction comes as the $2.96 billion market cap company trades near its 52-week high of $9.47, with InvestingPro data showing a remarkable 9.95% return over the past week.
The prices for the sales ranged from $9.16 to $9.41. Following the transaction, Shah directly owns 267,235 shares of Amneal Pharmaceuticals. According to InvestingPro analysis, the stock’s RSI indicates overbought territory, while the company maintains a GREAT overall financial health score. Investors can access 12 additional exclusive ProTips and comprehensive valuation metrics through InvestingPro’s detailed research report.
In other recent news, Amneal Pharmaceuticals reported its Q2 2025 earnings, revealing a significant earnings per share (EPS) performance that exceeded expectations. The company achieved an EPS of $0.25, which was higher than the anticipated $0.17, resulting in a 47.06% surprise. However, the company’s revenue fell short of projections, totaling $725 million against the forecasted $748.18 million. Despite the revenue miss, the earnings report was well-received. The positive earnings surprise was a key highlight for investors evaluating the company’s recent performance. Analyst firms have not provided any new upgrades or downgrades in the wake of these results. These developments are part of the latest updates surrounding Amneal Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.